Who is the CEO of Bio Medica Laboratories Ltd?
- Answer Field
-
Pradeep Mehta is the Chairman and Managing Director of Bio Medica Laboratories Ltd.
How to Schema
Bio Medica Laboratories Ltd is a pharmaceutical manufacturing company engaged in producing injectable formulations for human and veterinary healthcare applications. The Bio Medica Laboratories IPO will open for subscription on May 21, 2026, and close on May 25, 2026. The IPO consists of 37,72,000 shares with a price band of ₹132 to ₹139 per share and is proposed to be listed on the SME platform of NSE. The company plans to utilise the issue proceeds for loan repayment, setting up a new manufacturing facility at the existing premises, and general corporate purposes. Investors can apply for the IPO through the ASBA process using net banking or UPI-supported trading platforms before the issue closing date.
Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on injectable medicines used in human and veterinary healthcare. The company manufactures liquid injections and dry powder injections in single-dose and multi-dose formats. Its product portfolio includes generic medicines, branded formulations, and over-the-counter (OTC) products. Operating through a business-to-business (B2B) contract manufacturing model, the company develops formulations according to client-specific requirements and packaging specifications. The company also holds Good Manufacturing Practices (GMP) certification issued by the Food & Drugs Administration, Madhya Pradesh. The company operates two manufacturing facilities in Indore, Madhya Pradesh, and supplies products for pharmaceutical companies under contractual arrangements. Its operations are linked to the pharmaceutical manufacturing segment, particularly injectable formulations used across different healthcare applications.
Investors planning to apply for the Bio Medica Laboratories Ltd IPO can do so through the ASBA (Application Supported by Blocked Amount) process available via net banking or through UPI-enabled trading applications. Applicants are required to log in to their trading or banking platform, select the IPO section, choose Bio Medica Laboratories Ltd IPO, enter the bid quantity and price within the stated price band, and approve the UPI mandate or ASBA request before the issue closing date.
For more details, visit the Bio Medica Laboratories IPO page.
Details | Information |
IPO Date | May 21, 2026 to May 25, 2026 |
Issue Size | 37,72,000 shares (agg. up to ₹52.43 Cr) |
Price Band | ₹132 to ₹139 per share |
Lot Size | 1,000 shares |
Listing At | SME, NSE |
Market Maker | Prabhat Financial Services Ltd. |
Repayment of loan
Enhancement of the company’s existing production capabilities by setting up of new manufacturing facility at the existing premises
General corporate purposes
Event | Date |
|---|---|
IPO Open Date | Thu, May 21, 2026 |
IPO Close Date | Mon, May 25, 2026 |
Tentative Allotment | Tue, May 26, 2026 |
Initiation of Refunds | Wed, May 27, 2026 |
Credit of Shares to Demat | Wed, May 27, 2026 |
Tentative Listing Date | Fri, May 29, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Mon, May 25, 2026 |
₹132 to ₹139 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,78,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,78,000 |
S-HNI (Min) | 3 | 3,000 | ₹4,17,000 |
S-HNI (Max) | 7 | 7,000 | ₹9,73,000 |
B-HNI (Min) | 8 | 8,000 | ₹11,12,000 |
The Bio Medica Laboratories IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the trading platform.
Go to the IPO section to view active IPO listings.
Locate Bio Medica Laboratories IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 1000 shares) within the price band of ₹132 to ₹139 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Bio Medica Laboratories IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
QIB Shares Offered | 36,000 | 1.00% | 0.95% |
NII (HNI) Shares Offered | 17,55,000 | 48.98% | 46.53% |
− bNII > ₹10L | 11,70,000 | - | 31.02% |
− sNII < ₹10L | 5,85,000 | - | 15.51% |
Retail Shares Offered | 17,92,000 | 50.01% | 47.51% |
Firm Reservations | |||
Market Maker Shares Offered | 1,89,000 | - | 5.01% |
Total Shares Offered | 37,72,000 | 100.00% | 100.00% |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹17.57 crore in FY23 to ₹39.12 crore as of March 2025.
Total Income: Recorded at ₹38.33 crore in March 2025, as compared to ₹16.25 crore in FY23.
Profit After Tax (PAT): Reported at ₹9.79 crore in March 2025, and ₹0.33 crore in FY23.
Net Worth: Recorded at ₹14.73 crore in March 2025 compared to ₹2.44 crore in FY23.
Reserves & Surplus: Stood at ₹5.55 crore in March 2025, as compared to ₹2.34 crore in FY23.
Total Borrowings: Stood at ₹15.01 crore in March 2025, as compared to ₹9.61 crore in FY23.
EBITDA: Stood at ₹15.21 crore in March 2025 in comparison to ₹1.70 crore in FY23.
The company reported growth in its asset base during the reported financial period, reflecting an expansion in operational scale and business activities.
Income levels showed an upward trend over the period under review, indicating increased business operations and higher revenue generation from core activities.
Profitability improved during the reported period, supported by growth in business performance and operational execution.
The company’s net worth strengthened over time, reflecting changes in retained earnings and overall financial position.
Reserves and surplus recorded growth during the period, indicating an increase in accumulated earnings within the business.
Borrowings also increased during the reported financial years, reflecting the company’s financing requirements for operational and business-related activities.
Operating performance, as reflected through EBITDA, showed improvement over the review period, indicating changes in earnings generated from core business operations before finance costs, taxes, depreciation, and amortisation.
The company’s financial performance reflects expansion in operations alongside developments in profitability and operational capacity during the stated period.
The company operates through a contract manufacturing business model, which may result in dependence on client-specific orders, agreements, and continuation of business relationships with pharmaceutical companies.
The pharmaceutical manufacturing industry is subject to regulatory approvals, quality standards, and compliance requirements. Any changes in regulations, certifications, or operational compliance may affect business operations and manufacturing activities.
The proposed utilisation of IPO proceeds towards setting up a new manufacturing facility may support expansion in production capabilities and operational capacity over time.
The company operates in the pharmaceutical injectable segment and manufactures products catering to both human and veterinary healthcare requirements, which provides exposure to multiple healthcare-related applications and business segments.
KPI | Nov 30, 2025 | Mar 31, 2025 |
ROE | 54.41% | 99.59% |
ROCE | 23.22% | 48.20% |
Debt/Equity | 2.23 | 1.02 |
RoNW | 54.41% | 99.59% |
PAT Margin | 30.35% | 25.64% |
EBITDA Margin | 47.11% | 39.83% |
Price to Book Value | - | 8.66 |
Registrar | Lead Manager(s) |
|---|---|
Skyline Financial Services Pvt. Ltd. | Narnolia Financial Services Ltd. |
Plot No. 11B-11C,
Sector-E, Sanwer Road
Industrial Area, Industrial Estate (Indore),
Indore, Madhya Pradesh, 452015
Phone: +91 7314102751
Email: companysecretary@biomedica.co.in
Website: https://biomedica.co.in/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Bio Medica Laboratories IPO allotment status.
Pradeep Mehta is the Chairman and Managing Director of Bio Medica Laboratories Ltd.
The Bio Medica Laboratories IPO is scheduled to open for subscription on May 21, 2026, and close on May 25, 2026. The shares are proposed to be listed on the NSE SME platform.
Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations, including liquid injectables and dry powder injectables for human and veterinary healthcare applications. The company operates on a B2B contract manufacturing model and develops formulations according to client requirements. Its operations are supported by GMP and GLP certifications and manufacturing facilities located in Indore, Madhya Pradesh. The long-term sustainability of the business may depend on factors such as regulatory compliance, client relationships, manufacturing capacity utilisation, and demand within the pharmaceutical sector.
The Bio Medica Laboratories IPO consists of 37,72,000 equity shares with an aggregate issue size of ₹52.43 crore. The IPO is being launched through the book-building process on the SME platform of NSE.
The ‘pre-apply’ facility allows investors to submit their IPO application details before the official issue opening date. The mandate for payment authorisation is generally completed once the IPO subscription window opens. This feature is available through selected trading and investment platforms that support IPO applications.
The lot size for the Bio Medica Laboratories IPO is 1,000 shares. Retail investors are required to apply for a minimum of two lots, which amounts to 2,000 shares. Based on the upper end of the price band, the minimum application amount is approximately ₹2,78,000.
The tentative basis of allotment for the Bio Medica Laboratories IPO is expected to be finalised on May 26, 2026. Following allotment finalisation, shares are expected to be credited to eligible investors’ Demat accounts before the proposed listing date.
Skyline Financial Services Pvt. Ltd. has been appointed as the registrar to the Bio Medica Laboratories IPO. The registrar is responsible for processing IPO applications, allotment-related activities, and investor-related queries associated with the issue.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the Bio Medica Laboratories IPO through the ASBA process using net banking facilities or through UPI-enabled trading applications. The application process generally involves logging into the trading or banking platform, selecting the IPO section, entering the bid quantity and price within the specified price band, providing the UPI ID where required, and authorising the payment mandate before the issue closing date.
Yes, a valid Demat account is generally required to apply for an IPO in India. In the event of allotment, the shares are credited electronically to the investor’s Demat account before listing on the stock exchange.
Investors can check the allotment status through the registrar’s website after the basis of allotment is finalised. If shares are allotted, they are credited to the investor’s Demat account before the listing date. In case shares are not allotted, the blocked application amount is released as per the applicable process.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading